New York, New York--(Newsfile Corp. - January 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Blue Owl Capital Inc. (NYSE: OWL) between February 6, 2025 and November 16, 2025, inclusive (the "Class Period"), of the important February 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Blue Owl securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Blue Owl Capital Inc. (NYSE: OWL) between February 6, 2025 and November 16, 2025, inclusive (the “Class Period”), of the important February 2, 2026 lead plaintiff deadline. SO WHAT: If you purchased Blue Owl securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Blue Owl Capital Inc. during the specified Class Period of the upcoming lead plaintiff deadline on February 2, 2026 [1]. Group 1: Class Action Details - Investors who bought Blue Owl securities between February 6, 2025, and November 16, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit claims that Blue Owl made false or misleading statements regarding its asset base and liquidity issues, which led to investor damages when the truth was revealed [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4].

New York, New York--(Newsfile Corp. - January 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Blue Owl Capital Inc. (NYSE: OWL) between February 6, 2025 and November 16, 2025, inclusive (the "Class Period"), of the important February 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Blue Owl securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

thTORONTO, Jan. 23, 2026 /PRNewswire/ - Blue Moon Metals Inc. ("Blue Moon" or the "Company") (TSXV: MOON) (Z: BMM) (Frankfurt: 8SX0), today announced that on Monday January 26, its common shares will commence trading on the Nasdaq Capital Market under the symbol "BMM". The common shares will continue to trade on the TSXV Venture Exchange under the symbol "MOON" and the Frankfurt Stock Exchange under the symbol "8SX0" but will no longer trade on the OTCQX under the symbol "BMOOF". Upon commencement of tradi ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Blue Owl Capital Inc. securities between February 6, 2025, and November 16, 2025, of the upcoming lead plaintiff deadline on February 2, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Blue Owl securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 2, 2026 [2]. - The lawsuit alleges that Blue Owl made false or misleading statements and failed to disclose significant liquidity issues and pressures from business development companies (BDCs) [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company and ranking highly in the number of settlements since 2013 [3]. Group 3: Case Specifics - The lawsuit claims that Blue Owl faced undisclosed liquidity issues due to BDC redemptions, which led to a potential limitation or halt of redemptions, thereby misleading investors about the company's true operational status [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Blue Owl Capital Inc. during the specified class period of the upcoming lead plaintiff deadline on February 2, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Blue Owl securities between February 6, 2025, and November 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements recovered for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Blue Owl made false or misleading statements regarding its asset base and liquidity issues, which were not disclosed to investors [4]. - It is claimed that these misrepresentations led to damages for investors when the true situation was revealed [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Blue Owl Capital Inc. securities between February 6, 2025, and November 16, 2025, of the upcoming lead plaintiff deadline on February 2, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Blue Owl securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 2, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Blue Owl made false or misleading statements and failed to disclose critical information regarding its asset base and liquidity issues stemming from business development companies' redemptions [5]. - It is claimed that Blue Owl was likely to limit or halt redemptions of certain BDCs, and the defendants downplayed the severity of these issues, leading to materially misleading statements about the company's business and prospects [5]. - The lawsuit asserts that when the true details became known, investors suffered damages as a result [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Blue Owl Capital Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on February 2, 2026 [1]. Group 1: Class Action Details - Investors who bought Blue Owl securities between February 6, 2025, and November 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by February 2, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Blue Owl made false or misleading statements regarding its asset base and liquidity issues, which were not disclosed to investors [5]. - It is claimed that Blue Owl faced pressure from business development companies (BDCs) redemptions, leading to potential limitations or halts on redemptions, which were downplayed in public statements [5].

Core Insights - Amgen has acquired Dark Blue Therapeutics Ltd., a UK-based biotechnology company, for a transaction valued at up to $840 million, enhancing its oncology portfolio with a novel investigational small molecule aimed at treating acute myeloid leukemia (AML) [1][2]. Company Overview - Amgen is a leading biotechnology company that discovers, develops, manufactures, and delivers innovative medicines for various diseases, including cancer, heart disease, and rare diseases, leveraging over 40 years of industry experience [4]. - The company has been recognized as one of the "World's Most Innovative Companies" and "America's Best Large Employers," and is part of the Dow Jones Industrial Average and Nasdaq-100 Index [5]. Acquisition Details - The acquisition introduces a small molecule that targets and degrades two proteins (MLLT1/3) associated with specific types of AML, showing promising anti-cancer activity in preclinical models [2]. - Amgen plans to integrate Dark Blue Therapeutics into its existing research organization, which will bolster its early oncology discovery efforts and align with its strategy to invest in novel therapeutic targets [3].